NHS Launches Gene Database to Assess Cancer Risk
A new database from the NHS focusing on genes associated with cancer is set to help patients and families in England understand their risk of developing the disease.
Individuals will have their genetic data compared to an unprecedented register featuring 120 genes known to elevate the chances of cancer, according to NHS England.
Those identified with an inherited risk will be offered routine screenings for specific cancers like breast and prostate cancer. Moreover, there is potential for patients to be tested for their responsiveness to certain treatments, leading to more personalized care.
Health Secretary Wes Streeting described this initiative as a “life-changing and life-saving” tool that could accelerate screenings and facilitate earlier detection of multiple types of cancer.
Each year, tens of thousands of cancer patients and individuals with a familial history of the disease receive genetic testing through the NHS. Those with a heightened risk profile will be included in this new database.
Individuals on this register will receive customized advice on reducing their risk or detecting cancer at an earlier stage.
The NHS is developing this register as part of a 10-year strategy aimed at enhancing cancer prevention and treatment.
NHS England’s national cancer director shared on BBC Radio 4’s Today programme that this is the first time any healthcare system has centralized all genetic risk information.
Prof Peter Johnson mentioned that this register consolidates existing tests for cancer susceptibility, enabling outreach for screenings and, in some instances, preventative treatments.
This approach allows healthcare providers to monitor patients and introduce new tests and therapies as they become available, while ensuring strict confidentiality and security, he noted.
He acknowledged that discovering one’s cancer risk can feel quite overwhelming, but underlined that early detection is key.
The NHS National Inherited Cancer Predisposition Register follows a similar initiative for Lynch syndrome, which successfully offered routine preventative screenings to over 12,000 at-risk individuals.
Charlie Grinstead, who was diagnosed with bowel cancer in 2020, shared that his Lynch syndrome diagnosis enabled him to receive immunotherapy after chemotherapy failed, describing it as “the key to my recovery.”
Streeting remarked, “One in every two people will get cancer in their lifetime, but that doesn’t mean the odds are random—many have a higher risk due to inherited genes.” He emphasized that while we can’t change these genes, we can leverage this information effectively.
He affirmed that this “world-leading genetic register” would facilitate earlier personalized and preventative care.
“This register won’t merely boost innovation; it will be life-changing and life-saving, equipping the NHS to provide tailored care and expedited screenings to catch more cancers earlier,” he explained.
Claire Rowney, CEO of Breast Cancer Now, remarked that this move could “transform the lives of women” at an elevated risk for breast cancer due to their genetics or family history.
She emphasized the necessity for the register to be accessible to all clinicians and crafted to ensure coordinated care for those with increased risk profiles.
